相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer
Burcu F. Darst et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer
Ryon P. Graf et al.
EUROPEAN UROLOGY (2020)
Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma
Julia S. Gerke et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations
Changxue Lu et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2020)
Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry
Jiao Yuan et al.
PLOS GENETICS (2020)
Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes
Jennifer L. Beebe-Dimmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
Laura S. Graham et al.
PLOS ONE (2020)
Loss of DNA mismatch repair proteins in prostate cancer
Meenal Sharma et al.
MEDICINE (2020)
A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data
Minh-Phuong Huynh-Le et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2020)
Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience
Eirik Viste et al.
SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE (2020)
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men
Laurie Tonon et al.
EUROPEAN UROLOGY (2019)
SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer
Silvia Hernandez-Llodra et al.
PROSTATE (2019)
Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer
H. Ballentine Carter et al.
EUROPEAN UROLOGY (2019)
EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)
Thomas B. L. Lam et al.
EUROPEAN UROLOGY (2019)
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
Wassim Abida et al.
JAMA ONCOLOGY (2019)
Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease
A. Kamoun et al.
ANNALS OF ONCOLOGY (2018)
Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations
Rene Bottcher et al.
BMC CANCER (2018)
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Yi-Mi Wu et al.
CELL (2018)
CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer
Diogo A. Bastos et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2018)
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
Veda N. Giri et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Alan Ashworth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants
Tokhir Dadaev et al.
NATURE COMMUNICATIONS (2018)
Cumulative Evidence for Relationships Between 8q24 Variants and Prostate Cancer
Yu Tong et al.
FRONTIERS IN PHYSIOLOGY (2018)
Germline variation at 8q24 and prostate cancer risk in men of European ancestry
Marco Matejcic et al.
NATURE COMMUNICATIONS (2018)
NCCN Guidelines® Insights Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 Featured Updates to the NCCN Guidelines
Mary B. Daly et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death
Rong Na et al.
EUROPEAN UROLOGY (2017)
Prognostic outlier genes for enhanced prostate cancer treatment
Hyun Kim et al.
FUTURE ONCOLOGY (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer
Mark M. Pomerantz et al.
CANCER (2017)
Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer
Gretchen K. Hubbard et al.
CANCER RESEARCH (2016)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
C. C. Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Integrative Clinical Genomics of Advanced Prostate Cancer (vol 161, pg 1215, 2015)
Dan Robinson et al.
CELL (2015)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Arun A. Azad et al.
CLINICAL CANCER RESEARCH (2015)
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington et al.
CLINICAL CANCER RESEARCH (2014)
SPINK1 Protein Expression and Prostate Cancer Progression
Richard Flavin et al.
CLINICAL CANCER RESEARCH (2014)
The emerging role of speckle-type POZ protein (SPOP) in cancer development
Ram-Shankar Mani
DRUG DISCOVERY TODAY (2014)
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1
John R. Prensner et al.
LANCET ONCOLOGY (2014)
Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants
Jian An et al.
CELL REPORTS (2014)
SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts
Mirjam Blattner et al.
NEOPLASIA (2014)
Genetic markers associated with early cancer-specific mortality following prostatectomy
Wennuan Liu et al.
CANCER (2013)
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Kai-Hsiung Chang et al.
CELL (2013)
Tracking the clonal origin of lethal prostate cancer
Michael C. Haffner et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Nuclear PTEN Controls DNA Repair and Sensitivity to Genotoxic Stress
C. Bassi et al.
SCIENCE (2013)
Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer
A. Brandt et al.
ANNALS OF ONCOLOGY (2012)
Concordance of Tumor Differentiation Among Brothers with Prostate Cancer
K. Fredrik Jansson et al.
EUROPEAN UROLOGY (2012)
The DNA damage response and cancer therapy
Christopher J. Lord et al.
NATURE (2012)
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Christopher E. Barbieri et al.
NATURE GENETICS (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Comparison of scores for bimodality of gene expression distributions and genome-wide evaluation of the prognostic relevance of high-scoring genes
Birte Hellwig et al.
BMC BIOINFORMATICS (2010)
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
Philip A. Watson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
Yu Chen et al.
LANCET ONCOLOGY (2009)
The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling
Sari Tuupanen et al.
NATURE GENETICS (2009)
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype
A. Mitra et al.
BRITISH JOURNAL OF CANCER (2008)
TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis
Outi R. Saramaki et al.
CLINICAL CANCER RESEARCH (2008)
Concordance of survival in family members with prostate cancer
Kari Hemminki et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
G. Attard et al.
ONCOGENE (2008)
Recurrent gene fusions in prostate cancer
Chandan Kumar-Sinha et al.
NATURE REVIEWS CANCER (2008)
Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer
R. K. Nam et al.
BRITISH JOURNAL OF CANCER (2007)
Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex
Hannelore V. Heemers et al.
ENDOCRINE REVIEWS (2007)
Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement
Maisa Yoshimoto et al.
NEOPLASIA (2006)
Genetic susceptibility to prostate cancer
G Cancel-Tassin et al.
BJU INTERNATIONAL (2005)
The adrenal androgen Androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor
A Mizokami et al.
CANCER RESEARCH (2004)
分享论文
